Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new cancer diagnostic system based on a CDK profiling technology.

Hideki Ishihara1, Tomokazu Yoshida, Yuko Kawasaki

  • 1Central Research Laboratories, Sysmex Corporation, 4-4-4, Takatsukadai, Nishi-ku, Kobe 651-2271, Japan. Hideki_Ishihara@sysmex.co.jp

Biochimica Et Biophysica Acta
|July 2, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Chain Fatty Acid Oxidation Disorder Genes: A Comprehensive Genetic Database of LC-FAOD Variants, Genotypes, and Phenotypes.

Human mutation·2026
Same author

A Four-Year Prospective Pilot Study of Newborn Screening for Late-Onset Proximal Urea-Cycle Disorders in Hyogo Prefecture in Japan.

International journal of neonatal screening·2026
Same author

Perioperative and Oncological Outcomes of Colorectal Cancer Surgery in Obese Patients: A Multicenter Retrospective Study.

Annals of gastroenterological surgery·2026
Same author

Interspecific Differences in the Effects on Embryos Between Freshwater and Marine Fish Exposed to Water-Accommodated Fractions Derived From Very-Low Sulfur Fuel Oil.

Environmental toxicology·2026
Same author

Fully Automated Serum LC-MS/MS Platform and Pediatric Reference Intervals for Organic Acids, Amino Acids, and Acylcarnitines in Children (Ages 0-6 Years): Toward Quantitative Diagnosis of Inborn Errors of Metabolism.

Diagnostics (Basel, Switzerland)·2026
Same author

Impact of Aspirin on Recurrence Prevention After Curative Resection for Stage I-III Colorectal Cancer: A Multi-Institutional Retrospective Study.

Journal of surgical oncology·2026

CDK profiling, a novel method measuring cyclin-dependent kinase (CDK) activity and expression, shows promise for gastrointestinal cancer diagnosis. Elevated CDK2 activity in tumors suggests its potential as a diagnostic biomarker.

Area of Science:

  • Molecular pathology
  • Oncology
  • Biomarker discovery

Background:

  • Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation and implicated in cancer.
  • Despite extensive knowledge of CDK roles in cancer, clinical diagnostic applications are limited by a lack of suitable technology.
  • CDK profiling offers a potential solution for translating molecular insights into clinical practice.

Purpose of the Study:

  • To investigate the clinical relevance of CDK profiling in gastrointestinal carcinoma tissues.
  • To establish novel methods and apparatus for analyzing CDK expression and activity in tumor tissue lysates.
  • To assess the diagnostic potential of CDK profiling for gastrointestinal cancers.

Main Methods:

  • Development of novel methods and apparatus for CDK expression and activity analysis.

Related Experiment Videos

  • Analysis of CDK profiles in 30 surgically dissected gastrointestinal carcinomas and matched normal mucosal specimens.
  • Comparison of CDK activity and expression patterns between tumor and normal tissues.

    • Main Results:

    • Elevated CDK2 activity was observed in over 70% of gastrointestinal carcinoma tissues.
    • G1-CDK activity profiling accurately reflected proliferation differences between tumor and normal colonic tissues.
    • The developed methods demonstrated feasibility for clinical settings.

    Conclusions:

    • CDK profiling is a potent molecular-clinical approach complementing conventional pathological diagnosis.
    • CDK profiling can aid in the individualized treatment of gastrointestinal cancers.
    • Further validation of CDK profiling may lead to improved cancer diagnostics and personalized medicine.